<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271699</url>
  </required_header>
  <id_info>
    <org_study_id>MS01/2011</org_study_id>
    <nct_id>NCT01271699</nct_id>
  </id_info>
  <brief_title>Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis</brief_title>
  <official_title>Multiple Sclerosis and Fabry Disease: Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis - an Epidemiological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The association of Multiple Sclerosis (MS) and Fabry disease is known from own clinical
      experiences as well as from case reports in the literature, where symptoms and suspicious
      results in the brain MRI led to the misdiagnosis of Fabry patients as MS. Remarkably, those
      patients almost never showed oligoclonal bands or an intrathecally derived IgG-production was
      wrongly assumed due to misinterpretation of CSF results. Where oligoclonal bands were
      present, concomitant diagnoses had to be discussed. Furthermore, those patients showed no
      involvement of the spinal cord, as evidenced by MRI. Beside the possible complications of a
      not-effective and not-necessary MS therapy, those patients are at risk of irreparable organ
      damage due to the delayed implementation of enzyme replacement therapy for Fabry disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fabry disease is an X-linked lysosomal disorder that leads to excessive deposition of neutral
      glycosphingolipids in the vascular endothelium of several organs in the body. Progressive
      endothelial accumulation of glycosphingolipids accounts for the associated clinical
      abnormalities of skin, eye, kidney, heart, brain, and peripheral nervous system. Fabry
      disease manifesting predominantly in men. Female heterozygotes also present with features of
      Fabry disease. In Europe the prevalence of Fabry disease seems to be massively
      underrepresented.

      Multiple Sclerosis (MS, Encephalomyelitis disseminata) ist the most common inflammatory
      disease of the central nervous system (CNS). The first clinical manifestation peaks in the
      3rd-4th decade. 2.5 million Young adults are affected worldwide. In Germany the prevalence
      rate reaches approx. 100 patients per 100,000 inhabitants. Females are more frequently
      affected (2-3:1). The underlying causes of the disease are not sufficiently explored yet. The
      genetic backgrounds as well as environmental factors are involved. An autoimmune mediated
      process, driven by activated T-lymphocytes and macrophages, leads to inflammatory
      demyelination and axonal loss.

      Magnetresonance imaging of the brain and spinal cord, evaluation of the cerebrospinal fluid
      to detect intrathecally derived immunoglobulin production (IgG) and a comprehensive
      diagnostic workup on other possible causes of the symptoms. The modern diagnostic criteria
      (McDonald criteria, 2001 + revisions 2005) demand the proof of the dissemination of the
      inflammatory process in space and time, either by clinical or radiological terms.

      The evaluation of the cerebrospinal fluid aims at the confirmation of an intrathecally
      derived synthesis of IgG. In 98% of the patients oligoclonal bands can be detected during the
      course of the disease. This parameter is highly sensitive but only low specific. The
      diagnostic criteria allow making the diagnosis of &quot;certain&quot; or at least &quot;probable&quot; MS without
      the confirmation of oligoclonal bands.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">250</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fabry diagnostic will be done centrally: blood samples will be stored for analysis of
      a-galactosidase in blood, Gb3 as well as lyso-Gb3. In all cases direct analysis of the gene
      will be done, especially in females where due to the Lyonisation effect a-galactosidase
      activity might be normal in blood although the patient might suffer from Fabry disease.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis
        according to the McDonald diagnostic criteria for Multiple Sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at age 18-50 years old with a confirmed or probably diagnosis of Multiple
             Sclerosis according to the McDonald diagnostic criteria for MS

          -  Patients with confirmed diagnosis of Multiple Sclerosis according to the McDonald
             diagnostic criteria but without confirmation of oligoclonal IgG in the CSF

          -  Patients with present oligoclonal IgG in the CSF but without proof of dissemination of
             spinal inflammatory processes in the MRI

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients being younger than 18 years or older than 50 years

          -  Patients without performed MRI of the brain and spinoaxis

          -  Patients with a structural change in the brain that is not caused by a chronic
             inflammatory disease of the CNS

          -  Missing signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Klink für Neurologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamillusklinik, Abtl. Neurologie</name>
      <address>
        <city>Asbach</city>
        <zip>53567</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin Charite, Klinisches und experimentelles Forschungszentrum für Multiple Sklerose</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus Berlin, Abt. Neurologie</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HHU Düsseldorf, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus Rüttenscheid, Abt. Neurologie</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg, Neurovaskuläre AG</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augustahospital AnholT GmbH, Abt. Neurologie</name>
      <address>
        <city>Isselburg</city>
        <zip>46419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Münster, Klinik &amp; Poliklinik für Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock, Zentrum für Nervenheilkunde</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Bamherzigen Brüder Trier, Neurologische Klinik</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Würzburg, Neurologische Klinik</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009 Mar;40(3):788-94. doi: 10.1161/STROKEAHA.108.526293. Epub 2009 Jan 15.</citation>
    <PMID>19150871</PMID>
  </reference>
  <reference>
    <citation>Falke K, Büttner A, Schittkowski M, Stachs O, Kraak R, Zhivov A, Rolfs A, Guthoff R. The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):523-34. doi: 10.1007/s00417-008-0962-9. Epub 2008 Oct 18.</citation>
    <PMID>18931853</PMID>
  </reference>
  <reference>
    <citation>Fellgiebel A, Keller I, Marin D, Müller MJ, Schermuly I, Yakushev I, Albrecht J, Bellhäuser H, Kinateder M, Beck M, Stoeter P. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009 Jan 6;72(1):63-8. doi: 10.1212/01.wnl.0000338566.54190.8a.</citation>
    <PMID>19122032</PMID>
  </reference>
  <reference>
    <citation>Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007 Jan;9(1):34-45.</citation>
    <PMID>17224688</PMID>
  </reference>
  <reference>
    <citation>Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005 Nov 19;366(9499):1794-6. Erratum in: Lancet. 2006 Dec 23;368(9554):2210.</citation>
    <PMID>16298216</PMID>
  </reference>
  <reference>
    <citation>McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7.</citation>
    <PMID>11456302</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the &quot;McDonald Criteria&quot;. Ann Neurol. 2005 Dec;58(6):840-6. Review.</citation>
    <PMID>16283615</PMID>
  </reference>
  <reference>
    <citation>Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group. [Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. Nervenarzt. 2002 Jun;73(6):556-63. Review. German.</citation>
    <PMID>12243005</PMID>
  </reference>
  <reference>
    <citation>Callegaro D, Kaimen-Maciel DR. Fabry's disease as a differential diagnosis of MS. Int MS J. 2006 Jan;13(1):27-30.</citation>
    <PMID>16420782</PMID>
  </reference>
  <reference>
    <citation>Saip S, Uluduz D, Erkol G. Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg. 2007 May;109(4):361-3. Epub 2007 Jan 17.</citation>
    <PMID>17234336</PMID>
  </reference>
  <reference>
    <citation>Invernizzi P, Bonometti MA, Turri E, Benedetti MD, Salviati A. A case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble? Mult Scler. 2008 Aug;14(7):1003-6. doi: 10.1177/1352458508092355. Epub 2008 Jul 16.</citation>
    <PMID>18632784</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Arndt Rolfs</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Fabry Disease</keyword>
  <keyword>Fabry´s Disease</keyword>
  <keyword>Anderson-Fabry Disease</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

